BioSpace News Archive

Biora Therapeutics, Inc today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration.

Zhongchao Inc. today announced the introduction of its Patient-Reported Outcome (PRO) -based symptom management model.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the opening of another RightSource SM facility, and first in the United Kingdom, which will provide services to the Stevenage advanced therapies biocluster. RightSource is a flexible biologics testing lab, operated and managed by Charles River, making fast, reliable quality control (QC) more accessible to a broader reach of companies.

Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the publication of new preclinical data demonstrating linsitinib reduced pathologic bone marrow activity in a mouse model of TED.

Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support.

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first patient in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-184 in patients with advanced solid tumors.

Arcutis Biotherapeutics, Inc. announced the launch of an educational campaign designed to elevate understanding, connection, and encouragement for those living with seborrheic dermatitis, or Seb Derm for short.

Daewoong Therapeutics confirmed the approval from the Ministry of Food and Drug Safety (MFDS) for a phase 1 clinical trial plan for its investigational product DWRX2008.

Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a genome-wide methylome approach, announced today the closing of $48 million in financing.

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, to be held on October 1-4, 2023 in Toronto, ON, Canada.